Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
June 30, 2008

Numoda to Provide DOR Biopharma with Clinical Trial Services

  • DOR BioPharma has contracted Numoda for services related to its Phase III trial of orBec® for the treatment of gastrointestinal graft-versus-host disease. Numoda will also take an equity position in DOR common stock.

    DOR will gain access to services including benchmarking capabilities that will allow the firm to develop operational and financial plans. Barring any unforeseen modifications to the Phase III program, Numoda will guarantee the agreed clinical trial budget against cost overruns.

    In addition, Numoda will also provide a data lock at the end of the clinical trial, which, will reportedly expedite completion of the study while also increasing quality.